Shows
Surfing the MASH Tsunami6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior ChangeSend us a textThis conversation is the second segment of SurfingMASH's coverage of the Global Think Tank on Steatotic Liver Diseases (#SLDThinkTank2025) held in Barcelona in June. It focuses on the kinds of feedback most likely to produce successful behavioral interventions.The conversation begins with Jörn discussing the Liver Screen Study, a "very ambitious effort" that starts with 30,000 members of the general European population, narrows down to a subgroup with liver disease, and then provides these individuals with information about MASLD and how to manage it, ultimately evaluating its impact. Many of these peo...2025-07-2816 min
EASL PodcastsEASL Studio Podcast: Why does WHO engagement with Steatotic Liver Disease matter?This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E7: The impact of p...2024-10-0336 min
L'invité de CIO RadioEchosens : La bonne pratique pour diagnostiquer les maladies du foie | Jean-Baptiste Thumerel, Directeur Logiciel d'EchosensJean-Baptiste Thumerel, Directeur Logiciel Echosens, nous explique pourquoi sa société a fait le choix d’un cloud Amazon, cela est extrêmement rare dans le milieu médical. Il nous donne ensuite es caractéristiques de son produit phare « Fibroscan » qui est vendu dans le monde entier. Enfin, Jean-Baptiste Thumerel nous renseigne sur le parcours proposé par le groupe pour les médecins traitants, qui va au-delà du simple diagnostic.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.2024-03-2015 min
ehealth radio networkThe Role of FibroScan® in the Multi-Modal Management of Patients with Chronic Liver DiseaseDr. Tejas Joshi, Director of Liver Diseases and Assistant Professor at Marshall University School of Medicine in Huntington, WV joins eHealth Radio and the Liver Health and Health News Channels. Listen to interview with host Eric Michaels and guest Dr. Tejas Joshi discuss the following: Could you give an overview of what FibroScan is, and discuss why you decided to implement this into your practice?How do you feel that the use of FibroScan has benefitted your practice and your unique patient population?We’ve covered considerable benefits of this tool for patients. What is the value of FibroScan to the...2023-03-0412 min
ehealth radio networkFatty Liver Disease in Children: Prevalence, Evaluation, & Essential ToolsDr. Alisha Mavis, a Pediatric Hepatologist at Duke University where she cares for pediatric patients with liver disease joins eHealth Radio and the Children's Health & Health News Channels. Listen to interview with host Eric Michaels and guest Dr. Alisha Mavis discuss the following: What is the prevalence of fatty liver disease in children, and who should we be screening?When screening a child for fatty liver disease, what are some of the tools used to evaluate for the disease, and how is the diagnosis of pediatric fatty liver disease made?What is the natural history of pediatric liver disease, and...2023-02-1715 minSurfing the MASH TsunamiS4-E4.2 - Surfing NASH Community Interview with Jerry Mabary of ChronwellIn a thematic debut, Jörn Schattenberg and Roger Green host interviews with three listeners from the Surfing NASH community to discuss four prominent questions around:the “straightjacket” of biopsyhow we think about “tests” when not classed as "NITs" as compared to biopsyhow do we all become better centered on patient needsthe idea of combination therapyIn this second installment, Jerry Mabary joins Roger to discuss NASH-TAG 2023 and the future of Fatty Liver. Jerry previously appeared on the podcast when he worked at Echosens and led their side of the LIVErHEALTHY launch. Now he has joined Chronwell, a LIVErHE...2023-01-2125 minSurfing the MASH TsunamiS3-E49.5 - From the Vault: The NICE Draft Guidance vs. The Economics of NAFLD: A Bad FitThis conversation From the Vault comes from Season 3 Episode 13.4, part of NASH Tsunami’s coverage of the first NICE meeting on FibroScan. Season 3, Episode 13 looks at the NICE Draft Guidance Evaluating FibroScan use in Community and Primary Care settings. This conversation focuses on underlying tensions between a methodology designed to assess big-ticket spending on critical moments of disease and a population screening approach that centers on wellness care more than illness care.The conversation starts with Roger Green noting an inherent tension between short-term health economic tests driving a decision not to compensate and longer-term hea...2022-10-1614 min
Medication TalkManaging Nonalcoholic Fatty Liver DiseaseTRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Me...2022-08-0128 minSurfing the MASH TsunamiS3-E33.2 - #ILC2022 Looking Back: Patient Engagement 2 -- Patient CommunicationDuring last week's #ILC2022 meeting in London, Louise Campbell took the opportunity to sit down with PBC Foundation CEO and Fatty Liver patient Robert Mitchell-Thain to discuss patient engagement from their own perspectives, Louise as a longtime hepatology nurse and Robert as a patient advocate and NAFLD patient.Robert starts by discussing his own experience with Fatty Liver disease. First, he notes the importance of patients boldly defining themselves as patients and taking ownership of the word "Patient." As he notes, doctors are only involved with patients during brief, infrequent office visits while patients themselves live the...2022-07-0316 min
Diabetes Knowledge into Practice PodcastNASH: Advances in non-invasive screening | With Dr Kenneth CusiThis is a special episode brought to you in association with Hepatology Knowledge into Practice.
NASH occurs in around 20% of individuals with NAFLD, and puts patients at high risk of poor outcomes including cardiovascular events and hepatocellular carcinoma. With people with type 2 diabetes and obesity at significantly increased risk for developing NAFLD, how can we identify those with NASH?
In this podcast episode, we are joined by Dr Kenneth Cusi to discuss how patients can be risk stratified using non-invasive biomarkers and imaging techniques.
By completing this activity you can qualify for 0.25 CME...2022-05-1614 min
L'invité de SC RadioEchosens, la Supply Chain un vecteur de performance en constante évolution après la crise sanitaire | Jeremy Landon, Supply Chain ManagerJérémy Landon à l’origine de la naissance du département supply chain du groupe ECHOSENS, pionnier dans le domaine de l’élastographie hépatique, nous explique les différentes contraintes logistiques qu’on peut avoir sur le marché de la santé. Il nous éclaire quant à la digitalisation, la modernisation et comment a su s’adapter la supply chain de l'entreprise au travers de la crise sanitaire ainsi que les différentes alternatives pour présager les ruptures du stock … Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.2022-05-1113 minSurfing the MASH TsunamiS3-E13.4 - The NICE Draft Guidance vs. The Economics of NAFLD: Not a Great FitEpisode 13 looks at the NICE Draft Guidance Evaluating FibroScan use in Community and Primary Care settings. This conversation focuses on underlying tensions between a methodology designed to assess big-ticket spending on critical moments of disease and a population screening approach that centers on wellness care more than illness care.This conversation starts with Roger Green noting an inherent tension between short-term health economic tests driving a decision not to compensate and longer-term healthcare priorities that rely on patients who cannot afford the test being able to take it. Ian Rowe describes this as a tension inherent in...2022-03-0614 minSurfing the MASH TsunamiS3-E13.2 - NICE Assesses FibroScan Screening: Health Economics & NAFLDEpisode 13 looks at the NICE Draft Guidance Evaluating FibroScan use in Community and Primary Care settings. This conversation focuses on some of the data issues surrounding this evaluation, ranging from the lack of the long-term data necessary to make the wellness case to narrower, more case-specific flaws in how costing data was developed. The previous conversation looks at how NICE analyzes procedures and ways this approach might conflict with the economics of NAFLD screening. This conversation starts with Ian Rowe noting that NICE depends on the manufacturer to provide data for the analysis, but Echosens only presented o...2022-03-0513 min
Surfing the MASH TsunamiS2-E9.2—Drug-Free Treatment of Early Fatty Liver Disease: Issues for Public HealthDonna Cryer joins the Surfers to consider some of the public health issues and implications surrounding treatment of Early Fatty Liver disease and related metabolic diseases. EXTRA: Louise Campbell discusses her public health-driven motivation to form Tawazun Health.This episode is sponsored by Echosens. Echosens is partnering with Chronwell and ModifyHealth to offer LIVErHEALTHY, an integrated program of non-invasive monitoring, technology-supported behavior support, nutritional counseling and delivery of medically-tailored meals.After focusing solely on identify and motivation, the Surfers switch focus to consider public health issues. Donna Cryer discusses specific challenges linked to d...2021-03-0712 min
Surfing the MASH TsunamiS2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver diseaseExecutives from Echosens, Chronwell and ModifyHealth join to introduce LIVErHEALTHY, their integrated program for early Fatty Liver disease that integrates non-invasive monitoring, technology-supported behavior support, nutritional counseling and delivery of medically-tailored meals. This episode is sponsored by Echosens. to introduce LIVErHEALTHY. Echosens is partnering with Chronwell and ModifyHealth to offer LIVErHEALTHY, an integrated program of non-invasive monitoring, technology-supported behavior support, nutritional counseling and delivery of medically-tailored meals. In this conversation, our sponsors introduce the LIVErHEALTHY program. First Dr. Juan Pablo Frías discusses why behavioral, lifestyle and diet interventions are so important in t...2021-03-0732 min
Surfing the MASH TsunamiS2-E9.1—Drug-Free Treatment of Early Fatty Liver Disease: Identity mattersDonna Cryer and Roger Green lead a conversation of why identity matters for patients trying to resolve fatty liver disease without medication, while Stephen Harrison and Louise Campbell discuss some of their methods for doing so.This episode is sponsored by Echosens. Echosens is partnering with Chronwell and ModifyHealth to offer LIVErHEALTHY, an integrated program of non-invasive monitoring, technology-supported behavior support, nutritional counseling and delivery of medically-tailored meals.In this conversation, the group discusses ways that patient identify is pivotal in success. Roger Green and Donna Cryer discuss the "Why", while Stephen Harrison...2021-03-0712 min
Surfing the MASH TsunamiS2-E9 - Novel Approaches to Drug-Free Treatment of Early Fatty Liver DiseaseDonna Cryer joins the Surfers to discuss the importance of identity in lifestyle modification, after which our sponsors from Echosens present LIVErHEALTHY, a program that combines non-invasive testing, technology-enabled behavior support and a food and nutrition element. Over the past two weeks, we have discussed the idea that diagnostic development in Fatty Liver Disease are progressing faster than medication. This episode looks at the issue of non-pharmacologic therapy from two points of view. First, Donna Cryer joins the Surfers to consider the role identity and self-definition play in the patient's ability to integrate healthy diet a...2021-03-041h 05